MaxCyte (NASDAQ:MXCT) Announces Quarterly Earnings Results

MaxCyte (NASDAQ:MXCT) released its quarterly earnings report on Tuesday. The company reported a loss of ($0.10) earnings per share (EPS) for the quarter, which was better than the expected consensus estimate of ($0.14) by $0.04, as noted by financial analysts. Despite the positive earnings surprise, MaxCyte recorded a negative net margin of 78.36% and a negative return on equity of 16.00%.

MaxCyte Stock Performance

During trading on Tuesday, the stock of MaxCyte increased by $0.05, reaching a price of $3.47. The trading volume for the day was 563,159 shares, slightly below its average volume of 592,048 shares. Over the past year, MaxCyte's stock has seen a low of $3.16 and a high of $5.26. With a market capitalization of $367.68 million, the stock has a P/E ratio of -10.21 and a beta of 1.35. Additionally, the fifty-day moving average sits at $4.25 while the 200-day moving average is $4.00.

About MaxCyte

MaxCyte, Inc. is a life sciences company that focuses on the discovery, development, and commercialization of next-generation cell therapies in the United States and globally. The company offers several products, including the ExPERT ATx, a static electroporation instrument for small to medium-scale transfection; the ExPERT STx, which is used for flow electroporation in protein production and drug development; and the ExPERT GTx, designed for large-scale transfection in therapeutic applications. Furthermore, MaxCyte provides ExPERT VLx for large volume cell-engineering.

Investment Consideration

Potential investors should consider gathering more information before deciding whether to invest in MaxCyte. Analysts have identified additional stocks with strong potential that might be better investment options compared to MaxCyte. Despite a current Buy rating among analysts, research suggests that other stocks may be more favorable for investment.

MaxCyte, Earnings, NASDAQ